StockData
Abbott Laboratories logo

Abbott Laboratories

ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$110.16+3.96 (+3.73%)

Close on Nov 2, 2026Market cap $190.62BP/E 35.4Yield 2.18%

Abbott Laboratories Core Laboratory — U.S. COVID-19 Testing Sales by Quarter

Core Laboratory — U.S. COVID-19 Testing Sales ($M) ($M)

QuarterlyAnnual

Abbott Laboratories Core Laboratory — U.S. COVID-19 Testing Sales: $1M in Q4 2024, unchanged from a year earlier. That is the lowest of the 13 quarters on record here. No newer figure appears in the documents we track.

Latest, Q4 2024
1
Period ended Dec 31, 2024
Change on a year earlier
0.0%
1 in Q4 2023
History
13 quarters
Since Q4 2021
Sources
9
Documents cited below

Where the Q4 2024 figure comes from

“|| Sales 4Q24 | COVID Tests Sales 4Q24 || Core Laboratory | 363 | 1,024 | 1,387 | 1 | 1 | 2”

Source: SEC Filing (0001628280-25-002092) ↗

Reported in Form 8-K Quarterly Earnings Releases (Item 2.02 Revenue Tables) & Form 10-K/10-Q MD&A.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedCore Laboratory — U.S. COVID-19 Testing Sales ($M) ($M)Year on yearSource
Q4 2024Dec 31, 202410.0%SEC Filing (0001628280-25-002092) ↗
Q3 2024Sep 30, 20241-50.0%SEC Filing (0001628280-24-042893) ↗
Q2 2024Jun 30, 20241-50.0%SEC Filing (0001628280-24-032182) ↗
Q1 2024Mar 31, 20241-50.0%SEC Filing (0001628280-24-016497) ↗
Q4 2023Dec 31, 20231-66.7%SEC Filing (0001628280-25-002092) ↗
Q3 2023Sep 30, 20232-50.0%SEC Filing (0001628280-24-042893) ↗
Q2 2023Jun 30, 20232-33.3%SEC Filing (0001628280-24-032182) ↗
Q1 2023Mar 31, 20232-60.0%SEC Filing (0001628280-24-016497) ↗
Q4 2022Dec 31, 20223-57.1%SEC Filing (0001628280-24-002009) ↗
Q3 2022Sep 30, 20224–SEC Filing (0001628280-23-034544) ↗
Q2 2022Jun 30, 20223–SEC Filing (0001628280-23-025156) ↗
Q1 2022Mar 31, 20225–SEC Filing (0001628280-23-012020) ↗
Q4 2021Dec 31, 20217–SEC Filing (0001628280-23-001516) ↗

Cite this data

StockData. (2026). Abbott Laboratories Core Laboratory — U.S. COVID-19 Testing Sales ($M), quarterly Q4 2021–Q4 2024 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/dx-cl-covid-us

See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.